子公司地图
注册国家
三个医生
Global Compliance
One-Stop Service
Medical Device
Health Food
Cosmetics
Foods
Value-added
Help Enterprises Reach Target Markets Faster
50
Regulatory Compliance and Clinical Trial Services across 50 Countries & Regions.
16
16 wholly-owned subsidiaries worldwide.
600
+
Trusted Partner to 600+ Leading Enterprises.
3000
+
Over 3,000 Successful Registrations & Certificates Issued.
Global Self-operated Matrix
More
With 16 global wholly-owned subsidiaries, WISELINK GROUP adheres to “Originated in Australia, Rooted in China, Serving the World”, providing global compliance and clinical trial services for healthcare and consumer product manufacturers.
Compliance Certification Expertise
More
Global Regulatory Tracking
More
With timeliness, accuracy and practicality at its core, WISELINK offers regulatory updates, interpretations and trend analysis to help businesses navigate global compliance and drive global growth.
Hong Kong MDACS Guidance Updated! All Changes at a Glance
The Medical Devices Division of Hong Kong’s Department of Health has released a full suite of updated GN guidance documents for MDACS, revising rules covering listing, Local Responsible Persons (LRPs), traders, IVDs and post-market incident reporting. MDACS is a voluntary listing scheme; however, applicable medical devices procured by the Hospital Authority must be MDACS-listed from 23 March 2026 onwards. Eligible products include Class II–IV General Medical Devices (GMD) and Class B–D In Vitro Diagnostic Medical Devices (IVDMD). It is clarified that pharmaceutical products, human blood/tissue products, animal-derived implantable products, standard PPE, cosmetics, refurbished devices, custom-made devices, and devices solely for research, teaching, exhibition or demonstration are excluded from the scheme. This update also distinguishes the roles of Guidance Notes (GN) and Codes of Practice (COP), introduces standalone COPs for LRPs, importers, manufacturers and distributors, and further refines the lists of in-scope and out-of-scope products. Relevant enterprises are advised to monitor these regulatory changes and adjust their compliance programmes in a timely manner.
2026-11-12
Health Canada Updates List of Recognized Standards for Medical Devices! Simplified Document Review Available for Certain Products
Health Canada’s revised List of Recognized Standards for Medical Devices took effect on November 2, 2026. It is the primary technical basis for MDL licence applications, regulating dossier drafting, test selection and conformity declarations. Manufacturers who meet listed standards and provide a Declaration of Conformity may skip raw test reports for corresponding items and speed up review. Still, standard compliance does not equal automatic approval; full evaluation of risk, clinical data and labelling is still required. The update covers newly added, revised and withdrawn standards. New ASTM, EN, IEC, ISO and CLSI standards are now recognized, spanning MRI compatibility, medical masks, emergency medical electrical equipment, surgical robots, breathing circuit biocompatibility, orthopaedic implants, contact lens care solutions and IVD specimen testing.
2026-11-11
FDA QMSR is Now in Effect! Fully Aligned with ISO 13485
On February 2, 2026, the FDA’s revised Quality Management System Regulation (QMSR) for medical devices officially took effect, marking the most significant reform to 21 CFR Part 820 since its issuance. By reference, QMSR incorporates ISO 13485:2016 as the statutory requirement for quality management systems and retires the long-standing QSIT inspection methodology. The FDA has simultaneously updated its FAQ document to clarify core matters including inspection requirements, scope of records, and transition arrangements following the effective date. Based on official FDA guidance, this article outlines key compliance points for enterprises. It also clarifies that QMSR and medical device registration are sequentially connected but target different regulatory subjects: registration assesses whether a product may be marketed in the US, while QMSR audits whether a manufacturing facility can consistently produce conforming products. The two intersect during FDA on-site inspections, particularly Pre-approval Inspections (PAI).
2026-11-10
Mutual Recognition among SG-MY-TH: How to Choose Your First Launch Route for Southeast Asia Market Layout
The Southeast Asian medical device market continues to expand. The gradual rollout of mutual recognition frameworks among Singapore, Malaysia and Thailand creates opportunities for overseas manufacturers to shorten registration timelines and cut compliance costs. This trilateral recognition scheme is not a universal one-certificate system. Instead, it is a complex framework featuring mutual recognition between Singapore and Malaysia, mutual recognition between Malaysia and Thailand, plus Thailand’s unilateral recognition of Singapore HSA approvals. This article systematically breaks down the trilateral recognition mechanisms, application pathways and compliance essentials. It also analyses the advantages of taking Malaysia as the first launch market and subsequently filing for Singapore and Thailand via mutual recognition routes, helping enterprises select their initial Southeast Asian market and properly manage their ASEAN go-to-market schedule.
2026-11-09
Contact Us
Fill Form
Whether you need more information or wish to cooperate with us, we will guide you through every step of the regulatory process. Subscribe to our newsletter for the latest global regulatory updates.